CVA
MCID: CRB039
MIFTS: 68

Cerebrovascular Disease (CVA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cerebrovascular Disease

Summaries for Cerebrovascular Disease

Disease Ontology: 11 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary: Cerebrovascular Disease, also known as cerebrovascular disorders, is related to basal ganglia cerebrovascular disease and stroke, ischemic, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Signal Transduction and Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs). The drugs Acetylcarnitine and Nimodipine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone marrow and heart, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia: 75 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2700)
# Related Disease Score Top Affiliating Genes
1 basal ganglia cerebrovascular disease 33.0 PLAT APOE
2 stroke, ischemic 32.6 SERPINA3 SELP PON1 PLAT NOTCH3 MTHFR
3 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 32.6 SERPINA3 NOTCH3 COL4A1
4 vascular dementia 32.5 SERPINA3 PON1 NOTCH3 MTHFR CBS APP
5 peripheral artery disease 32.4 SELP APOE APOB ACE
6 binswanger's disease 32.4 NOTCH3 APP APOE ACHE
7 mitral valve stenosis 32.2 SERPINA3 SELP PLAT F2 ACE
8 transient cerebral ischemia 32.2 SERPINA3 PLAT NOTCH3 MTHFR F2 APOE
9 dementia 32.1 SERPINA3 PON1 NOTCH3 CBS APP APOE
10 disease of mental health 32.1 SERPINA3 APP APOE ACHE ACE
11 hemorrhage, intracerebral 32.0 PLAT COL4A1 APP APOE ACE
12 ischemia 32.0 SELP PON1 PLAT APP ACE
13 supranuclear palsy, progressive, 1 32.0 SERPINA3 CBS APP APOE ACHE
14 brain small vessel disease 1 31.9 NOTCH3 COL4A1
15 vascular disease 31.9 SELP PON1 PLAT NOTCH3 MTR MTHFR
16 carotid stenosis 31.9 SELP MTHFR APOE ACE
17 thoracic outlet syndrome 31.9 PLAT F2
18 alzheimer disease, familial, 1 31.7 SERPINA3 PON1 NOTCH3 MTR CBS APP
19 moyamoya disease 1 31.6 SERPINA3 PLAT NOTCH3 MTHFR F2 ACTA2
20 mild cognitive impairment 31.6 SERPINA3 APP APOE ACHE
21 peripheral vascular disease 31.5 SERPINA3 SELP PLAT MTHFR F2 CBS
22 thrombophilia due to thrombin defect 31.5 SELP PLAT MTHFR F2 CBS
23 coronary heart disease 1 31.5 PON1 CX3CR1 APOE APOB ACE
24 hypercholesterolemia, familial, 1 31.5 APOE APOB ACE
25 atrial heart septal defect 31.5 PLAT MTHFR F2 ACE
26 aortic valve disease 2 31.5 SERPINA3 APOB ACE
27 arteries, anomalies of 31.4 SERPINA3 APOE APOB AGTR1 ACE
28 atherosclerosis susceptibility 31.4 SELP PON1 PLAT MTHFR CX3CR1 APOE
29 heart disease 31.4 SERPINA3 SELP PON1 PLAT MTR MTHFR
30 lipoprotein quantitative trait locus 31.4 SERPINA3 SELP PON1 PLAT MTR MTHFR
31 cerebral amyloid angiopathy, cst3-related 31.4 SERPINA3 NOTCH3 APP APOE
32 arteriosclerosis 31.4 SELP PON1 CBS APOE APOB ACE
33 migraine with or without aura 1 31.4 SERPINA3 NOTCH3 MTHFR F2 COL4A1 APOE
34 arteriovenous malformation 31.4 SERPINA3 PLAT F2
35 lipid metabolism disorder 31.4 SERPINA3 PON1 CBS APOE APOB ACE
36 carotid artery disease 31.4 SELP PON1 PLAT APOE APOB ACE
37 aortic valve insufficiency 31.3 PON1 F2 ACTA2 ACE
38 hyperhomocysteinemia 31.3 SELP PON1 PLAT MTR MTHFR F2
39 intracranial embolism 31.3 SELP PLAT F2 APOE ACE
40 hemiplegia 31.3 PLAT COL4A1 ACTA2
41 nominal aphasia 31.3 CBS APOE ACHE
42 sleep apnea 31.3 APOE APOB ACE
43 hypertension, essential 31.2 SERPINA3 SELP PON1 PLAT MTHFR F2
44 aphasia 31.2 PLAT CBS APP APOE
45 deficiency anemia 31.2 SERPINA3 PON1 MTR F2 ACE
46 intracranial thrombosis 31.2 SELP PLAT MTHFR F2
47 attention deficit-hyperactivity disorder 31.2 SERPINA3 APP APOE ACHE ACE
48 hydrocephalus 31.2 SERPINA3 PLAT MTHFR APP APOE ACE
49 eclampsia 31.2 MTHFR F2 ACE
50 pre-eclampsia 31.2 SELP PON1 PLAT MTHFR HOTAIR F2

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 38)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease, Familial, 1 Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Chronic Kidney Disease Decubitus Ulcer
Deficiency Anemia Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Impaired Intellectual Development Esophagitis
Familial Atrial Fibrillation Generalized Atherosclerosis
Heart Disease Hypertension, Essential
Hypertensive Encephalopathy Hypothyroidism
Intermediate Coronary Syndrome Intracranial Embolism
Intracranial Thrombosis Iron Deficiency Anemia
Labyrinthitis Malignant Essential Hypertension
Mitral Valve Disease Osteoporosis
Parkinson Disease, Late-Onset Peripheral Vascular Disease
Protein-Energy Malnutrition Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders
Transient Cerebral Ischemia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


tremor; back pain; angina pectoris; chest pain; headache; syncope; edema; pain; chronic pain; sciatica; seizures; vertigo/dizziness; equilibration disorder; sleeplessness; transient ischemic attacks, stereotypic symptoms

MGI Mouse Phenotypes related to Cerebrovascular Disease:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.45 ACE ACHE AGTR1 APOB APOE APP
2 growth/size/body region MP:0005378 10.39 ACE ACHE AGTR1 APOB APOE APP
3 nervous system MP:0003631 10.38 ACHE AGTR1 APOB APOE APP CBS
4 cardiovascular system MP:0005385 10.35 ACE ACHE ACTA2 AGTR1 APOB APOE
5 muscle MP:0005369 10.33 ACHE ACTA2 APOB APOE APP CBS
6 cellular MP:0005384 10.31 ACE APOB APOE APP CBS COL4A1
7 immune system MP:0005387 10.28 ACE ACHE AGTR1 APOB APOE APP
8 behavior/neurological MP:0005386 10.27 ACE ACHE AGTR1 APOE APP CBS
9 renal/urinary system MP:0005367 10.16 ACE AGTR1 APOE CBS COL4A1 CX3CR1
10 reproductive system MP:0005389 10.15 ACE ACHE APOB APOE APP CBS
11 liver/biliary system MP:0005370 10.14 ACE APOB APOE CBS MEG3 MTHFR
12 respiratory system MP:0005388 10.06 ACHE APOE CBS COL4A1 F2 MEG3
13 vision/eye MP:0005391 10.03 ACHE ACTA2 APOB APOE APP CBS
14 skeleton MP:0005390 10.02 APOE APP CBS CX3CR1 F2 HOTAIR
15 hematopoietic system MP:0005397 9.97 ACE ACHE AGTR1 APOE APP CBS
16 mortality/aging MP:0010768 9.86 ACE ACHE AGTR1 APOB APOE APP
17 integument MP:0010771 9.32 APOE APP CBS CX3CR1 F2 MTHFR

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 759)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8
2
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
3
Nadroparin Approved, Investigational Phase 4
4
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
5
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
6
Bupropion Approved Phase 4 31677-93-7, 34841-39-9, 34911-55-2 444
7
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
8
Ezetimibe Approved Phase 4 163222-33-1 150311
9
Thrombin Approved, Investigational Phase 4
10
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
11
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
12
Simvastatin Approved Phase 4 79902-63-9 54454
13
Atenolol Approved Phase 4 29122-68-7 2249
14
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
15
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
16
Histamine Approved, Investigational Phase 4 51-45-6 774
17
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696
18
Norepinephrine Approved Phase 4 51-41-2 439260
19
Doxazosin Approved Phase 4 74191-85-8 3157
20
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
21
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
22
Galantamine Approved Phase 4 357-70-0, 1953-04-4 9651
23
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
24
Baclofen Approved Phase 4 1134-47-0 2284
25
Argatroban Approved, Investigational Phase 4 74863-84-6 152951 92722
26
Propafenone Approved Phase 4 34183-22-7, 54063-53-5 4932
27
Dronedarone Approved Phase 4 141626-36-0 208898
28
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
29
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
30
Edaravone Approved, Investigational Phase 4 89-25-8 4021 70335
31
Allopurinol Approved Phase 4 315-30-0 2094 135401907
32
Insulin aspart Approved Phase 4 116094-23-6 16132418
33
Insulin glargine Approved Phase 4 160337-95-1 118984454
34
Pravastatin Approved Phase 4 81093-37-0 54687
35
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
36
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
37
Reviparin Approved, Investigational Phase 4 9041-08-1
38
Tizanidine Approved, Investigational Phase 4 51322-75-9 5487
39
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
40
Saxagliptin Approved Phase 4 361442-04-8 11243969
41
Quinidine Approved, Investigational Phase 4 56-54-2, 130-95-0, 804-63-7 1065 441074 3034034 8549
42
Triflusal Approved, Investigational Phase 4 322-79-2 9458
43
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
44
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
45
Esreboxetine Approved, Experimental, Investigational Phase 4 98769-81-4, 71620-89-8, 98819-76-2 65856
46
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
47
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
48
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
49
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
50
Ramipril Approved Phase 4 87333-19-5 5362129

Interventional clinical trials:

(show top 50) (show all 6848)
# Name Status NCT ID Phase Drugs
1 Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease Unknown status NCT04346862 Phase 4 Acetyl-L-carnitine hydrochloride 500mg;Placebo
2 Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) Unknown status NCT02684825 Phase 4
3 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
4 Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident Unknown status NCT02714478 Phase 4
5 Acute Cerebrovascular Events During Extracorporeal Circulation a Comparison of New Minimized Perfusion Circuit to Standard Cardiopulmonary Bypass Unknown status NCT00862160 Phase 4
6 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
7 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
8 A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent Unknown status NCT02446730 Phase 4 Prasugel;Clopidogrel
9 The Potential Effect of Omega3 Supplement in Fish Oil on Infarced Areas in the Brain and Improvement of Neurological Functions fo Ischemic Stroke Patients Unknown status NCT04386525 Phase 4
10 Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
11 Clinical Study of Argatroban in the Treatment of Acute Progressive Ischemic Stroke Unknown status NCT04275180 Phase 4 Argatroban
12 Resting State MRI Connectivity in Acute Ischemic Stroke: Serotonin Selective Reuptake Inhibitor (SSRI) in Enhancing Motor Recovery: a Placebo Controlled Study Unknown status NCT02767999 Phase 4 Fluoxetine;Placebo
13 A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke. Unknown status NCT01863277 Phase 4 Melatonin;placebo
14 The Differentiation and Treatment Scheme of TCM Key Syndromes for the Treatment of Acute Disabling Ischemic Stroke: a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Unknown status NCT04199455 Phase 4 Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules);Placebo
15 Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial. Unknown status NCT02728180 Phase 4 Xingnaojing injection
16 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
17 A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke Unknown status NCT04200781 Phase 4 Granules of Shengdi Dahuang Decoction;Placebo
18 An International Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Progesterone Combined Intranasal and Intramuscular Administration in Patients With Acute Hemorrhagic Stroke Unknown status NCT04143880 Phase 4 Progesterone
19 Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
20 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
21 Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
22 Moderate-intensity Rosuvastatin Plus Ezetimibe Versus High-intensity Rosuvastatin for Target LDL-C Goal Achievement in Patients With Recent Ischemic Stroke: a Randomized Clinical Trial Unknown status NCT03993236 Phase 4 Experimental: Rosuvastatin/Ezetimibe 10;Active Comparator: Rosuvastatin 20mg
23 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
24 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
25 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
26 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
27 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
28 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
29 Safety and Efficacy of the Tong-Fu-Xing-Shen Herbal Formula for Stroke-Associated Pneumonia (TFXSHF) Unknown status NCT04275219 Phase 4 Tongfu capsules;The Placebo of Tongfu capsules
30 Validation of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness in Patients Undergoing Robot Assisted Thyroidectomy Unknown status NCT02122367 Phase 4
31 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
32 The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
33 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
34 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
35 Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke Unknown status NCT00552916 Phase 4
36 A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
37 Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study Unknown status NCT02817503 Phase 4 Standard BP control;Moderate BP control;Intensive BP control
38 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
39 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
40 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
41 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
42 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
43 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
44 Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients Unknown status NCT02484027 Phase 4 Rosuvastatin
45 Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke Unknown status NCT01198496 Phase 4 Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
46 Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO Unknown status NCT01550588 Phase 4 Standard medical treatment
47 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
48 Efficacy of Creative Therapy for Stroke Patients Unknown status NCT01455155 Phase 4
49 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
50 TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT Unknown status NCT03529149 Phase 4

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentoxifylline
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: cerebrovascular disorders

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

Organs/tissues related to Cerebrovascular Disease:

MalaCards : Brain, Bone Marrow, Heart, Spinal Cord, Cortex, Endothelial, Bone

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 47726)
# Title Authors PMID Year
1
Acetazolamide improves cerebral hemodynamics in CADASIL. 53 62
20227091 2010
2
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 53 62
20485689 2010
3
The angiotensin II type 2 receptor in the brain. 53 62
19861353 2010
4
Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). 53 62
20028534 2009
5
APOE-related mortality: effect of dementia, cardiovascular disease and gender. 53 62
18237822 2009
6
Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. 53 62
19200547 2009
7
Observation of the density and size of cells in hippocampus and vascular lesion in thalamus of GFAP-apoE transgenic mice. 53 62
19633698 2009
8
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. 53 62
19417859 2009
9
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. 53 62
18985627 2009
10
CADASIL: extended polymorphisms and mutational analysis of the NOTCH3 gene. 53 62
19006080 2009
11
Report of two Chinese families and a review of Mainland Chinese CADASIL patients. 53 62
19167727 2009
12
MRI correlates of cognitive decline in CADASIL: a 7-year follow-up study. 53 62
19139365 2009
13
Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. 53 62
19542606 2009
14
Age and apoE associations with complex pathologic features in Alzheimer's disease. 53 62
18653200 2008
15
Association of apolipoprotein E genotype and cerebrovascular disease risk factors in a Turkish population. 53 62
18576210 2008
16
New therapeutic targets in the neurovascular pathway in Alzheimer's disease. 53 62
18625452 2008
17
Cystatin C expression in ischemic white matter lesions. 53 62
18261165 2008
18
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 53 62
18548143 2008
19
Association of blood pressure and genetic background with white matter lesions in patients with mild cognitive impairment. 53 62
18511756 2008
20
New biochemical markers in acute coronary syndromes. 53 62
18537608 2008
21
PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. 53 62
17052804 2008
22
Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. 53 62
17420019 2007
23
Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. 53 62
17220293 2007
24
Polymorphisms in apolipoprotein B and risk of ischemic stroke. 53 62
17595251 2007
25
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 53 62
17534460 2007
26
Silent brain infarction and platelet activation in obstructive sleep apnea. 53 62
17341649 2007
27
Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. 53 62
17212611 2007
28
A perspective on telmisartan and cardiovascular risk. 53 62
17938615 2007
29
Delapril plus indapamide: a review of the combination in the treatment of hypertension. 53 62
17506588 2007
30
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. 53 62
17192928 2006
31
Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. 53 62
17054909 2006
32
Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. 53 62
16945218 2006
33
Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily. 53 62
16894458 2006
34
Cognitive frailty: Predementia syndrome and vascular risk factors. 53 62
16023766 2006
35
Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. 53 62
16208431 2006
36
[The relationship between ApoE gene polymorphism and lipid parameters]. 53 62
16335008 2005
37
The spectrum of mutations for CADASIL diagnosis. 53 62
15995828 2005
38
Genetic variation of the intestinal fatty acid-binding protein 2 gene in carotid atherosclerosis. 53 62
16013194 2005
39
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephaloapthy (CADASIL): a hereditary cerebrovascular disease, which can be diagnosed by skin biopsy electron microscopy. 53 62
15798438 2005
40
Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? 53 62
15662026 2005
41
Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. 53 62
15681302 2005
42
T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. 53 62
15644279 2005
43
[Mutations of genes associated with thromboses in ischemic stroke in patients with primary antiphospholipid syndrome]. 53 62
16320685 2005
44
Carotid artery intima-media thickness and angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke. 53 62
15858957 2005
45
The FABP2 gene polymorphism in cerebrovascular disease. 53 62
15527447 2004
46
ACE genotype and cognitive decline in an African-Caribbean population. 53 62
15465635 2004
47
Plasma adrenomedullin and carotid atherosclerosis in atherothrombotic ischemic stroke. 53 62
15361766 2004
48
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. 53 62
15471834 2004
49
Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. 53 62
15016346 2004
50
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. 53 62
15161326 2004

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.36 SERPINA3 PON1 PLAT NOTCH3 F2 COL4A1
2 endoplasmic reticulum lumen GO:0005788 10.07 F2 COL4A1 APP APOE APOB
3 blood microparticle GO:0072562 9.86 APOE F2 PON1 SERPINA3
4 extracellular space GO:0005615 9.7 SERPINA3 SELP PON1 PLAT F2 COL4A1
5 intermediate-density lipoprotein particle GO:0034363 9.46 APOE APOB
6 high-density lipoprotein particle GO:0034364 9.43 PON1 APOE APOB

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cholesterol metabolic process GO:0008203 9.86 PON1 APP APOE APOB
2 positive regulation of CoA-transferase activity GO:1905920 9.8 APOE AGTR1
3 blood vessel diameter maintenance GO:0097746 9.8 ACE AGTR1 CBS
4 homocysteine metabolic process GO:0050667 9.78 MTHFR CBS
5 lipoprotein biosynthetic process GO:0042158 9.76 APOE APOB
6 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.73 AGTR1 ACE
7 lipoprotein catabolic process GO:0042159 9.71 APOE APOB
8 positive regulation of amyloid fibril formation GO:1905908 9.67 APP APOE
9 artery morphogenesis GO:0048844 9.63 NOTCH3 APOE APOB
10 low-density lipoprotein particle remodeling GO:0034374 9.43 APOE APOB AGTR1
11 negative regulation of long-term synaptic potentiation GO:1900272 9.1 CX3CR1 APP APOE

Molecular functions related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 modified amino acid binding GO:0072341 9.46 MTHFR CBS
2 heparin binding GO:0008201 9.32 SELP F2 APP APOE APOB
3 bradykinin receptor binding GO:0031711 9.26 AGTR1 ACE

Sources for Cerebrovascular Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....